Halozyme Therapeutics Increases Revenue Estimates Through 2025 and Beyond with New Acquisition
Halozyme Therapeutics, Inc., a leader in biopharmaceutical innovations, has announced an optimistic update regarding its financial estimates for both 2025 and 2026, highlighting the strength of its operations and expanding market opportunities. The company expects total revenue for 2025 to reach between $1.385 billion and $1.4 billion, marking a significant year-over-year growth of 36% to 38%. This growth is primarily fueled by its robust royalty revenue, projected at $865 million to $870 million, which anticipates an impressive increase of approximately 51% to 52% compared to the previous year.
For 2026, Halozyme has raised its expectations significantly, projecting total revenues to soar to between $1.71 billion and $1.81 billion, which translates into a 23% to 30% growth when juxtaposed with the earlier estimates for 2025. Additionally, the firm projects royalty revenue in 2026 to increase to between $1.13 billion and $1.17 billion, further signifying a 30% to 35% growth from the previous year. Underpinning these optimistic projections is the anticipated increase in adjusted EBITDA, expected to range from $1.125 billion to $1.205 billion.
The encouraging financial outlook is augmented by Halozyme's strategic acquisition of Surf Bio, Inc., a move announced in December 2025. This acquisition is anticipated to enhance Halozyme’s drug delivery capabilities through Surf Bio's proprietary hyperconcentration technology which aims to revolutionize the administration of antibodies and biologics. This innovative technology allows for higher concentrations of therapeutics, making the process of subcutaneous delivery more efficient and patient-friendly.
Dr. Helen Torley, President and CEO of Halozyme, emphasized the significance of these financial updates, stating that the growth reflects the company’s strong core business and the momentum achieved throughout 2025. Notably, she highlighted the success of the ENHANZE® business model which has seen demand increase globally, thereby validating its integrated approach to therapeutic delivery.
In 2025, Halozyme formed new partnerships and signed multiple licensing agreements for ENHANZE products, marking a pivotal year in its long-term growth strategy. The company’s new drug collaborations, including significant contributions from partners like Janssen, have reached global approvals for multiple commercially available products developed using Halozyme’s technology.
As Halozyme moves into the new year, the potential for expansion remains bright. By the end of 2026, the firm anticipates having 15 partner programs actively in development, as well as signing at least three new drug delivery licensing agreements, further consolidating its position within the biotech industry.
The acquisition of Surf Bio, costing an initial $300 million with potential milestone payments of up to $100 million, reflects Halozyme's commitment to innovation through investment in technology that improves patient treatment experiences. The company's proactive stance positions it favorably within the dynamic landscape of biopharmaceuticals.
Halozyme's headquarters is located in San Diego, California, where it is focused not only on expanding its drug delivery solutions but also enhancing patient outcomes through innovative methods. As part of its strategic roadmap, the company is poised to set new benchmarks in the industry, ensuring sustained value for investors and stakeholders well into the future.
For investors and stakeholders, these developments underscore Halozyme's dedication to driving growth and innovation while maintaining a strong focus on patient-centric solutions as it continues to navigate the complexities of the biopharmaceutical market.
For 2026, Halozyme has raised its expectations significantly, projecting total revenues to soar to between $1.71 billion and $1.81 billion, which translates into a 23% to 30% growth when juxtaposed with the earlier estimates for 2025. Additionally, the firm projects royalty revenue in 2026 to increase to between $1.13 billion and $1.17 billion, further signifying a 30% to 35% growth from the previous year. Underpinning these optimistic projections is the anticipated increase in adjusted EBITDA, expected to range from $1.125 billion to $1.205 billion.
The encouraging financial outlook is augmented by Halozyme's strategic acquisition of Surf Bio, Inc., a move announced in December 2025. This acquisition is anticipated to enhance Halozyme’s drug delivery capabilities through Surf Bio's proprietary hyperconcentration technology which aims to revolutionize the administration of antibodies and biologics. This innovative technology allows for higher concentrations of therapeutics, making the process of subcutaneous delivery more efficient and patient-friendly.
Dr. Helen Torley, President and CEO of Halozyme, emphasized the significance of these financial updates, stating that the growth reflects the company’s strong core business and the momentum achieved throughout 2025. Notably, she highlighted the success of the ENHANZE® business model which has seen demand increase globally, thereby validating its integrated approach to therapeutic delivery.
In 2025, Halozyme formed new partnerships and signed multiple licensing agreements for ENHANZE products, marking a pivotal year in its long-term growth strategy. The company’s new drug collaborations, including significant contributions from partners like Janssen, have reached global approvals for multiple commercially available products developed using Halozyme’s technology.
As Halozyme moves into the new year, the potential for expansion remains bright. By the end of 2026, the firm anticipates having 15 partner programs actively in development, as well as signing at least three new drug delivery licensing agreements, further consolidating its position within the biotech industry.
The acquisition of Surf Bio, costing an initial $300 million with potential milestone payments of up to $100 million, reflects Halozyme's commitment to innovation through investment in technology that improves patient treatment experiences. The company's proactive stance positions it favorably within the dynamic landscape of biopharmaceuticals.
Halozyme's headquarters is located in San Diego, California, where it is focused not only on expanding its drug delivery solutions but also enhancing patient outcomes through innovative methods. As part of its strategic roadmap, the company is poised to set new benchmarks in the industry, ensuring sustained value for investors and stakeholders well into the future.
For investors and stakeholders, these developments underscore Halozyme's dedication to driving growth and innovation while maintaining a strong focus on patient-centric solutions as it continues to navigate the complexities of the biopharmaceutical market.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.